EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 39 / No 3 (Mars 2023) Med Sci (Paris), 39 3 (2023) 262-264 References
Open Access
Issue
Med Sci (Paris)
Volume 39, Number 3, Mars 2023
Néphrologie pédiatrique : de grandes avancées et un futur rempli d’espoir
Page(s) 262 - 264
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2023024
Published online 21 March 2023
  1. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013 ; 369 : 649–658. [CrossRef] [PubMed] [Google Scholar]
  2. Witting C, Langman CB, Assimos D, et al. Pathophysiology and treatment of enteric hyperoxaluria. Clin J Am Soc Nephrol 2021; 16 : 487–95. [CrossRef] [PubMed] [Google Scholar]
  3. Skolarikos A, Neisius A, Petrik A, et al. EAU guidelines on urolithiasis. 2022. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urolithiasis-2022_2022-03-24-142444_crip.pdf. [Google Scholar]
  4. Pfau A, Grujic D, Keddis MT, et al. Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia. Nephrol Dial Transplant 2021; 36 : 945–8. [CrossRef] [PubMed] [Google Scholar]
  5. Lieske JC, Lingeman JE, Ferraro PM, et al. Randomized placebo-controlled trial of reloxaliase in enteric hyperoxaluria. NEJM Evid 2022; 1 (7). doi : 10.1056/EVIDoa2100053. [CrossRef] [Google Scholar]
  6. Lemoine S, Bacchetta J. Reloxaliase in enteric hyperoxaluria - The Recent Brake. NEJM Evid 2022; 1 (7). doi : https://doi.org/10.1056/EVIDe2200110. [CrossRef] [Google Scholar]
  7. Garrelfs SF, Frishberg Y, Hulton SA, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 2021; 384 : 1216–26. [CrossRef] [PubMed] [Google Scholar]
  8. Bacchetta J, Farlay D, Abelin-Genevois K, et al. Bone impairment in oxalosis: An ultrastructural bone analysis. Bone 2015 ; 81 : 161–167. [CrossRef] [PubMed] [Google Scholar]
  9. Bacchetta J, Lieske JC. Primary hyperoxaluria type 1: novel therapies at a glance. Clin Kidney J 2022; 15 : i17–22. [CrossRef] [PubMed] [Google Scholar]
  10. Joher N, Moktefi A, Grimbert P, et al. Early post-transplant recurrence of oxalate nephropathy in a patient with primary hyperoxaluria type 1, despite pretransplant lumasiran therapy. Kidney Int 2022; 101 : 185–6. [CrossRef] [PubMed] [Google Scholar]
  11. Sellier-Leclerc AL, Metry E, Clave S, et al. Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of 5 cases. J Nephrol Dial Transplant 2022 Oct 28:gfac295. [Google Scholar]
  12. Méaux MN, Sellier-Leclerc AL, Acquaviva-Bourdain C, et al. The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants. Pediatr Nephrol 2022; 37 : 907–11. [CrossRef] [PubMed] [Google Scholar]
  13. Soliman NA, Mabrouk S. Primary hyperoxaluria type 1 in developing countries: novel challenges in a new therapeutic era. Clin Kidney J 2022; 15 : i33–6. [CrossRef] [PubMed] [Google Scholar]
  14. Le Dudal M, Huguet L, Perez J, et al. Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning. J Clin Invest 2019 ; 129 : 2571–2577. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.